Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 1999

View Archived Issues

Superoxide dimutase product may reduce asthma and neurodevelopmental deficits in neonates

Preclinical trials demonstrate neuroprotective activity of Vertex's neurophilin compounds

Phase I/II data presented for MEDI-507 in steroid-resistant GvHD

Licensing opportunity from NIH: antisense oligonucleotides for treating restenosis

Positive results announced for D-chiro-inositol in type II diabetes trial

ID Biomedical receives FDA clearance for Velogene Rapid MRSA Assay

FDA approves same-day, second-eye treatment with Sunrise LTK system

Abgenix and U.S. Army to cooperate on antibody-based defenses against filoviruses

StressGen begins second phase I safety trial of HspE7

Hyseq presents therapeutic candidate for reducing blood clotting

Klinge presents new compounds with both antitumor and immunosuppressive effects

SB discovers new class of compounds with high affinity for several 5-HT receptor subtypes

Novel antitumor agents from Rutgers act as topoisomerase poisons

New series from Novo Nordisk useful for pain, inflammation, NIDDM, etc.

Salix updates rifaximin clinical development as BID therapy

Double-strength formulation of Esterom to be tested in phase III

Potassium channel openers in development at Abbott for various medical conditions

Hoechst Marion Roussel files for new indication of Refludan in U.S. and E.U.

AltaRex proposes increase in enrollment in OvaRex MAb trial

International patent covers Kowa's new ACAT inhibitors

Gilead and NeXstar merger up for stockholder approval this month

New, physiologically balanced plasma volume expander now available in the U.S.

Pierre Fabre and Rega Institute embark on hantavirus vaccine project

Gidazepam exerts differential anxiolytic effects depending on individual reaction to stress

Proposed market formulation of Ro-64-0796 bioequivalent to other capsule and liquid formulations

Talinolol proves effective in addition to conventional therapy in CHF

CSAID from Italfarmaco prevents de novo formation of B1 receptors

Novel class III antiarrhythmic agent presented at scientific forum by Russian researchers

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...